Sartorius AG

SRT3.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SRT3.DE stands at 13.6B. In comparison, PHIA.DE has a market cap of 43.4B. Regarding current trading prices, SRT3.DE is priced at €219.20, while PHIA.DE trades at €48.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SRT3.DE currently has a P/E ratio of 160.00, whereas PHIA.DE's P/E ratio is 13.73. In terms of profitability, SRT3.DE's ROE is +0.05%, compared to PHIA.DE's ROE of +0.03%. Regarding short-term risk, SRT3.DE is more volatile compared to PHIA.DE. This indicates potentially higher risk in terms of short-term price fluctuations for SRT3.DE.

SRT3.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SRT3.DE stands at 13.6B. In comparison, BTL.DE has a market cap of 29.6B. Regarding current trading prices, SRT3.DE is priced at €219.20, while BTL.DE trades at €58.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SRT3.DE currently has a P/E ratio of 160.00, whereas BTL.DE's P/E ratio is 30.31. In terms of profitability, SRT3.DE's ROE is +0.05%, compared to BTL.DE's ROE of -0.08%. Regarding short-term risk, SRT3.DE is more volatile compared to BTL.DE. This indicates potentially higher risk in terms of short-term price fluctuations for SRT3.DE.

SRT3.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SRT3.DE stands at 13.6B. In comparison, SRT.DE has a market cap of 13.7B. Regarding current trading prices, SRT3.DE is priced at €219.20, while SRT.DE trades at €176.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SRT3.DE currently has a P/E ratio of 160.00, whereas SRT.DE's P/E ratio is 127.83. In terms of profitability, SRT3.DE's ROE is +0.05%, compared to SRT.DE's ROE of +0.05%. Regarding short-term risk, SRT3.DE is less volatile compared to SRT.DE. This indicates potentially lower risk in terms of short-term price fluctuations for SRT3.DE.

SRT3.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SRT3.DE stands at 13.6B. In comparison, AFX.DE has a market cap of 5.1B. Regarding current trading prices, SRT3.DE is priced at €219.20, while AFX.DE trades at €58.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SRT3.DE currently has a P/E ratio of 160.00, whereas AFX.DE's P/E ratio is 32.91. In terms of profitability, SRT3.DE's ROE is +0.05%, compared to AFX.DE's ROE of +0.08%. Regarding short-term risk, SRT3.DE is less volatile compared to AFX.DE. This indicates potentially lower risk in terms of short-term price fluctuations for SRT3.DE.

SRT3.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SRT3.DE stands at 13.6B. In comparison, FIE.DE has a market cap of 4.7B. Regarding current trading prices, SRT3.DE is priced at €219.20, while FIE.DE trades at €55.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SRT3.DE currently has a P/E ratio of 160.00, whereas FIE.DE's P/E ratio is 30.83. In terms of profitability, SRT3.DE's ROE is +0.05%, compared to FIE.DE's ROE of +0.17%. Regarding short-term risk, SRT3.DE is more volatile compared to FIE.DE. This indicates potentially higher risk in terms of short-term price fluctuations for SRT3.DE.

SRT3.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SRT3.DE stands at 13.6B. In comparison, 1SXP.F has a market cap of 4.3B. Regarding current trading prices, SRT3.DE is priced at €219.20, while 1SXP.F trades at €28.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SRT3.DE currently has a P/E ratio of 160.00, whereas 1SXP.F's P/E ratio is 32.19. In terms of profitability, SRT3.DE's ROE is +0.05%, compared to 1SXP.F's ROE of +0.17%. Regarding short-term risk, SRT3.DE is less volatile compared to 1SXP.F. This indicates potentially lower risk in terms of short-term price fluctuations for SRT3.DE.

SRT3.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SRT3.DE stands at 13.6B. In comparison, GXI.DE has a market cap of 2.2B. Regarding current trading prices, SRT3.DE is priced at €219.20, while GXI.DE trades at €64.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SRT3.DE currently has a P/E ratio of 160.00, whereas GXI.DE's P/E ratio is 28.09. In terms of profitability, SRT3.DE's ROE is +0.05%, compared to GXI.DE's ROE of +0.05%. Regarding short-term risk, SRT3.DE is less volatile compared to GXI.DE. This indicates potentially lower risk in terms of short-term price fluctuations for SRT3.DE.

SRT3.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SRT3.DE stands at 13.6B. In comparison, MYD.DE has a market cap of 2.2B. Regarding current trading prices, SRT3.DE is priced at €219.20, while MYD.DE trades at €26.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SRT3.DE currently has a P/E ratio of 160.00, whereas MYD.DE's P/E ratio is -256.92. In terms of profitability, SRT3.DE's ROE is +0.05%, compared to MYD.DE's ROE of -0.12%. Regarding short-term risk, SRT3.DE is more volatile compared to MYD.DE. This indicates potentially higher risk in terms of short-term price fluctuations for SRT3.DE.

SRT3.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SRT3.DE stands at 13.6B. In comparison, 2B4.F has a market cap of 1.5B. Regarding current trading prices, SRT3.DE is priced at €219.20, while 2B4.F trades at €23.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SRT3.DE currently has a P/E ratio of 160.00, whereas 2B4.F's P/E ratio is 136.24. In terms of profitability, SRT3.DE's ROE is +0.05%, compared to 2B4.F's ROE of +0.18%. Regarding short-term risk, SRT3.DE is less volatile compared to 2B4.F. This indicates potentially lower risk in terms of short-term price fluctuations for SRT3.DE.

SRT3.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SRT3.DE stands at 13.6B. In comparison, MF6.DE has a market cap of 3.5M. Regarding current trading prices, SRT3.DE is priced at €219.20, while MF6.DE trades at €0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SRT3.DE currently has a P/E ratio of 160.00, whereas MF6.DE's P/E ratio is 0.25. In terms of profitability, SRT3.DE's ROE is +0.05%, compared to MF6.DE's ROE of -0.34%. Regarding short-term risk, SRT3.DE is less volatile compared to MF6.DE. This indicates potentially lower risk in terms of short-term price fluctuations for SRT3.DE.